

POSTER PRESENTATIONS

PP19

First Patient-Reported Experience using ^{99m}Tc -Tektrotyd at the Nuclear Medicine Service in Kosovo

A. Jashari, Republic of North Macedonia

PP20

COST Action 19114: A European Network Dedicated to Targeted Alpha Therapy (TAT) with Astatine-211

J-F. Gestin, France

PP21

Development of a kit preparation for radiolabelling of the SST2 receptor antagonist TECANT1 with technetium- 99m

A. Sawicka, Poland

PP22

Comparison of incubation times of three commercially available kits for preparation of ^{99m}Tc human serum albumin nanocolloids

B. Hudomalj, Slovenia

PP23

A new labelling method of ^{99m}Tc -PSMA-HBED-CC

S. Shiratori, Thailand

PP24

Influence of the radiolabeling method on in vitro and in vivo stability of a new radiotracer developed to target pancreatic beta cells

M. Ahmadi, France

PP25

Quality of Radiopharmaceutical Formulations at the Nuclear Medicine Unit, Korle-Bu Teaching Hospital, Ghana

A. Asidu, Ghana

PP26

Radioisotopic exchange reactions for biomolecule pet radiolabeling

Á. Erhard, Spain

PP27

Development of ready to use kit formulation for trastuzumab radioimmunoconjugates and identification of radiochemical purity as the first step in quality control of the final product

M. Arev, North Macedonia